Scott Gottlieb (L) and Comanche Biopharma CEO Scott Johnson
Comanche secures $75M to test preeclampsia siRNA in PhII, adds Scott Gottlieb to board
Comanche Biopharma, an siRNA biotech created by veterans of The Medicines Company, has reeled in a $75 million Series B to test its drug candidate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
